Skip to main content

Table 1 List of the eligibility criteria

From: A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

Inclusion criteria Exclusion criteria
1. written informed consent 1. possible surgical resection and/or radiotherapy with curative potential
2. age 18 years or older 2. dihydropyrimidine-dehydrogenase deficiency
3. histological verified pancreatic cancer in stage IVB (T1–4N0M1) 3. gastrointestinal obstruction
4. staging and CA19-9 serum level not older than 4 weeks 4. a known secondary neoplasm except a curative treatable basalioma of the skin or carcinoma in situ of the cervix uteri
5. histological verified over-expression of HER2/neu (immunological score 3+ or 2+ and HER2/neu gene amplification in FISH analysis) 5. a known hypersensitivity against any of the applied substances
6. at least one measurable lesion (≥ 2 cm in conventional CT scan or ≥ 1 cm in spiral CT scans) 6. clinically relevant disorder of the cardio-vascular system or other organs or a severe systemic disease that compromises the study protocol or the interpretation of the data
7. no prior radiation or chemotherapy 7. clinically manifest pulmonary disorder
8. performance-status 0–2 according to WHO/ECOG or ≥ 60 points on the Karnofsky scale 8. prior polyneuropathy
9. life expectancy of at least 3 months 9. a concomitant treatment with the virusstatic agents Sorivudin or its analogues
10. Left ventricular excretion fraction > 50% 10. pregnancy, breast feeding or absence of appropriate contraceptive measures
11. appropriate renal, liver and hematopoetic function defined by: 11. psychiatric disorders, drug abuse or other disorders, that compromise the informed consent
   a. neutrophils ≥ 1.5 × 109/l  
   b. hemoglobin ≥ 80 g/l  
   c. platelets ≥ 100 × 109/l  
   d. total bilirubin < 3 × normal  
   e. creatinine clearance ≥ 30 ml/min (Cockroft Gault)  
   f. transaminases  
i. < 2.5 × normal  
ii. < 5 × normal in case of liver metastases  
12. possibility of long-term follow up 12. concomitant participation in other clinical trials or participation within the last 4 weeks
13. negative pregnancy testing 13. any other disorder or treatment that poses a risk to the patient or is incompatible with the aims of this study